How can societal concerns for fairness be integrated in economic evaluations of health programs? Erik Nord, PhD, Senior Researcher, Norwegian Institute.

Slides:



Advertisements
Similar presentations
Elicitation methods Health care demands exceed resource supply Therefore, rationing is inevitable Many ways by which we can ration health care One is economic.
Advertisements

Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
Interpreting Social Values in Health Sarah Clark University College London Presentation to UCL Conference: ‘How Can We Set Priorities in Health Fairly?’
Quality of life and subjective well-being Paul Dolan Director, Centre for Well Being in Public Policy University of Sheffield, Sheffield, UK [But soon.
How do we achieve cost effective cancer treatments in the UK? Professor Peter Littlejohns Department of Public Health and Primary Care.
Justice and Economic Evaluation Prof. Dr. Jan Busschbach
Making Decisions in Health Care: Cost-effectiveness and the Value of Evidence Karl Claxton Centre for Health Economics, Department of Economics and Related.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
Decision Analysis. What is decision analysis? Based on expected utility theory Based on expected utility theory Used in conditions of uncertainty Used.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
Balancing efficiency and equity in formal economic evaluation of health care. Erik Nord, Senior Researcher, Norwegian Institute of Public Health, Professor.
Using a discrete choice experiment with duration to estimate values for health states on the QALY scale Nick Bansback Assistant Professor School of Population.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
1 Modelling valuations for the EQ-5D health states: an alternative model using differences in valuations Jennifer Roberts and Paul Dolan Sheffield Health.
Schneider Institute for Health Policy Heller School Brandeis University September Donald S. Shepard, Ph.D. Schneider Institute for Health Policy.
Estimating utilities from individual preference data Some introductory remarks by Tony O’Hagan.
The Panel on Cost-Effectiveness in Health and Medicine Marthe Gold City University of London 30 October, 2003.
Schneider Institute for Health Policy Heller Graduate School Brandeis University September by Donald S. Shepard, Ph.D. Schneider Institute for Health.
25 Sept 07 FF8 - Discrete Choice Data Introduction Tony O’Hagan.
Do we need economics in medicine?. Edmund Burke, 1790 dcist.com/2007/12/10/revisiting_edmu.php “…the age of chivalry is gone. That of sophisters, economists,
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
Measuring and valuing health outcome Montarat Thavorncharoensap, Ph.D. 1: Faculty of Pharmacy, Mahidol University 2. HITAP, Thailand.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
Overview of the EQ-5D Purpose and origins of the descriptive system.
Variation in the Delivery of Medical Care: Is More Better? Todd Gilmer, PhD Professor of Health Policy and Economics Department of Family and Preventive.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
1 OECD Handbook on Measuring Volume Output of Education and Health Chapter 3: Health Sandra Hopkins OECD Health Division June 2007.
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
IN THE NAME OF GOD Flagship Course on Health Sector Reform and Sustainable Financing; Module 4: : How to construct.
Cost-Effectiveness Thresholds Professor of Health Economics
Economic evaluation of drugs for rare diseases CENTRE FOR HEALTH ECONOMICS K Claxton, C McCabe, A Tsuchiya Centre for Health Economics and Department of.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
3/12/2009 Decision and Cost-Effectiveness Analysis James G. Kahn after Eran Bendavid When Rationality Falters: Limitations and Extensions of Decision Analysis.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
{ Challenges in cost-utility analysis in the critical care setting Ville Pettilä MD, PhD, A/P Helsinki University Hospital VP SFAI- veckan.
How Can Cost Effectiveness Analysis Be Made More Relevant to U.S. Health Care? Paul G. Barnett, PhD February 29, 2012.
Sample Size Determination in Studies Where Health State Utility Assessments Are Compared Across Groups & Time Barbara H Hanusa 1,2 Christopher R H Hanusa.
Make Nutrition Services Count: Cost-Effectiveness Research & Outcomes Research.
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
INTEGRATED ASSESSMENT AND PLANNING FOR SUSTAINABLE DEVELOPMENT 1 Click to edit Master title style 1 Evaluation and Review of Experience from UNEP Projects.
The ‘QALY Trap’: Can Maximizing Health Benefit Be Reconciled with Principles of Non-Discrimination? Paul T. Menzel, Ph.D. * December, 2004, for the Workshop.
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Issues in valuing health outcomes in terms of QALYs Group B: Norman Daniels, Mark Kamlet, Alistair McGuire, Erik Nord, George Torrance, Milton Weinstein.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
1 Are values cultural determined…..  Many believe that QoL is cultural determined  One of the starting points of the EuroQol group.
Why does SMC say NO We all want the most effective medicines All medicines cost money Health budgets are limited How do we choose?
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
Medical Ethics  A set of guidelines concerned with questions of right & wrong, of duty & obligation, of moral responsibility.  Ethical dilemma is a.
Economics of Complementary and Integrative Medicine: Where Do We Go From Here? Patricia M. Herman, ND, PhD, RAND Corporation IM4US Boston August 8, 2014.
Health and Wellbeing Impacts of Green and Blue Infrastructure: Critical Issues for Application of Cost Benefit Analysis for Policy Appraisal Dr Tim Taylor.
Global burden of diseases
Variation in health state preferences across local and international populations: East doesn’t meet West CADTH symposium Panel Session April 12, 2016.
Effect of framing of death on health state values obtained from DCEs
The valuation of disease-specific questionnaires for QALY analysis
Why do/should we do economic evaluation?
Outcomes: part II Emma Frew
Assessing value for money: principles, methods and issues
Measuring outcomes Emma Frew October 2012.
Elicitation methods Health care demands exceed resource supply
Introduction to Health Economics (1)
Presentation transcript:

How can societal concerns for fairness be integrated in economic evaluations of health programs? Erik Nord, PhD, Senior Researcher, Norwegian Institute of Public Health.

Standard economic evaluation: Cost-utility analysis (CUA) based on the Quality Adjusted Life Year (QALY) Strongly recommended and used in the UK by NICE. Also: US, Canada, Australia. Alternative: Cost-value analysis (CVA)

QALYs illustrated Utility B: 2 QALYs 0.6 A C: 6 QALYs Years

Issue 1: Variation in utility estimates. Multi-attribute utility instruments. Example: EQ-5D (preferred and recommended by NICE) Dimensions: Mobility, self care, usual activities, pain, depression/anxiety Levels: 1: No problem; 2: some problems; 3: severe problems Examples from value table: A: ca. 0.8 B: ca. 0.6

Issue 1: Differences between multi-attribute utility instruments (E.g. Nord, IJTAHC 1996) Consi- derable problem Moderate problem C=>M EQ-5D (UK tto) HUI D

Fairness issues

Gained life years in people with illness Utility. H=1.0 B=0.7 Life threatened X Y Society’s valuation: V(Y) mostly equal to V(X) (Equal Value of Life) Sources: Intuition. Harris Oregon 1991; Murray 1996; Nord 1999; Johannesson 2002; Nord, Richardson & Menzel, Self interest: Ex post to illness: V(Y) mostly equal to V(X) Ex ante: Anticipation?

Fairness continued: Severity (concerns for the worse off ) X Y Theories of justice, government commissions: V(X) > V(Y)

Severity continued: Evidence in health economics Utility H=1.0 B=0.7 A=0.4 X Y Direct societal valuation: V(X) not = 2 V(Y) but = V(Y) Nord; Ubel et al; Dolan; Richardson;

Fairness continued: Non-fatal disease: Realising a person’s potential Utility H=1.0 B=0.7 A=0.4 X Y Norwegian Government Commission 1987: X and Y equally entitled. Norman Daniels late eighties: ’Best outcomes/fair chances’. Health economics literature: V(Y) > ½ V(X) (Nord, Pinto, Dolan and Cookson )

Issue 4: Value as a function of the number of years gained

Societal views on duration Abel Olsen, Norway, 1994: 100 persons, 10 years gained = 80 persons, 20 years gained Dolan and Cookson, York Regional Health Authority, 1998: Little differentiation between 10 and 20 years gained.

Conclusion so far QALY calculations may give quite poor guidance for priority setting, due to: 1. Lacking concern for severity. 2. Too strong emphasis on capacity to benefit.

Example of poor guidance NICE, EQ-5D: P reventing 50 cases of ’some problems with walking and with usual activities, no other problems’.... is as valuable as preventing 10 cases of fatal heart attack.

What to do? General rule: If important aspect, change formal model. If marginal aspect, take into account informally in decision making.

(1) Valuing gained life years in less than full health Refrain from quality adjusting gained ’liveable’ life years. (Nord et al 1999, cfr also DALYs.)

(2) Valuing different quantities of gained life years More direct research needed on the value of duration. Possible modifications of the model: Increased discount rate. Disregard years above a certain number.

(3) Valuing gains in functioning/QoL: Transformation of utilities. (Nord, 1996, cfr. Nord, Richardson, Pinto et al, 1999.) Values for valuing change 1.0 B’ 0.95 A’ 0.8 Utilities from the viewpoint of healthy A:0.4 B:

Example of transformation: EQ-5D EQ-5D Societal value for priority setting A (21222) B (21211) A=>B B=>Healthy A=>Healthy (Nord E, Annals of Medicine 2001, 33, ).

Hypothesis: Some convergence between individual utility and societal value.

The ’Utility Subtraction Method’ (USM) for valuing gains in QoL Problem: V(B=>A) Conventional procedure: (1) Measure ex ante utility of A and B (2) V(B=>A) = U(A) – U(B) Rationale: Feasibility: If n states, n/2(n-1) changes. Question: The validity of equation (2).

Intuition/plausibility: Will group A below necessarily be only half as interested in treatment as group B? If not, could this also show up in informed insurance preferences? States valued by community sample (mostly in normal health) Y X A B Groups in state X with potentials for full health and state Y respectively

Pilots at NIPH N ~ 30 Department of Mental Health Mainly psychologists. Some doctors and other academics.

Theme 1: The strength of desire for treatment (ex post to illness) 1 Healthy Bedridden

Opinions, theme 1: How many believed patients A would be much more (>>) or more (>) interested in treatment than patients B? A>>B A>B A=B N A: 7 => 2 B: 7 => A: 6 => 2 B: 6 => Anticipation in insurance decisions?

Insurance, life threatening illnesses (pilot at NIPH) Illness A: p = 10 %, 20 years to be gained from treatment. Illness B: p = 20 %, 7 years to be gained from treatment. Expected utility of insurance: A: 0.1 x 20 = 2 years B: 0.2 x 7 = 1,4 years Preferences: A: 12 B: 19 Implied discount rate: 8-9 %.

Conclusions If comparison of ’value for money’ in different areas of health care is of interest to decision makers: then QALYs may serve as a first step ….. provided there is no quality adjustment of desired, gained life years.. and in a next step, numbers from existing QALY tools are transformed to account for –concerns for the worse off; –wishes not to discriminate unduly against those with lesser potentials. Considerable data to support such cost-value analysis already exists. More research is welcome.